MACULAR ATROPHY INCIDENCE IN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR-TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Risk Factor Evaluation for Individualized Treatment Need of Ranibizumab or Aflibercept According to an Observe-and-Plan Regimen.

Détails

Ressource 1Télécharger: 29370035_BIB_160E4E5271F0.pdf (162.57 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY-NC-ND 4.0
ID Serval
serval:BIB_160E4E5271F0
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
MACULAR ATROPHY INCIDENCE IN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR-TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Risk Factor Evaluation for Individualized Treatment Need of Ranibizumab or Aflibercept According to an Observe-and-Plan Regimen.
Périodique
Retina
Auteur(s)
Mantel I., Dirani A., Zola M., Parvin P., De Massougnes S., Bergin C.
ISSN
1539-2864 (Electronic)
ISSN-L
0275-004X
Statut éditorial
Publié
Date de publication
05/2019
Peer-reviewed
Oui
Volume
39
Numéro
5
Pages
906-917
Langue
anglais
Notes
Publication types: Journal Article ; Observational Study
Publication Status: ppublish
Résumé
To investigate factors associated with macular atrophy (MA) incidence in neovascular age-related macular degeneration treated with either ranibizumab or aflibercept in an Observe-and-Plan variable dosing regimen.
Information was obtained from two identical prospective treatment protocols using ranibizumab or aflibercept in a variable dosing regimen termed "Observe and Plan." Eyes without MA at baseline were included. New atrophy at the final 2-year visit was investigated with univariate and multivariate analysis to identify associated risk factors, focusing on treatment factors.
De novo MA developed in 63 (42%) of 149 eyes/patients (mean age 79.0 years), in 70 eyes treated using aflibercept and 79 eyes using ranibizumab. The univariate analysis showed multiple associations of MA with baseline factors, of which the following were confirmed as independent risk factors after multivariate stepwise logistic regression: lower number of anti-vascular endothelial growth factors injections (P = 0.011), depigmentation (P = 0.0004), reticular pseudodrusen (P = 0.0005), lower baseline visual acuity (P = 0.0006), and retinal angiomatous proliferation (P = 0.001). The drug type showed no significant association with MA incidence (P = 0.21).
Within the variable dosing regimen, MA incidence was higher when fewer injections were required. More injections, if required by disease activity, did not increase the risk for MA.
Mots-clé
Aged, Angiogenesis Inhibitors/administration & dosage, Angiogenesis Inhibitors/adverse effects, Atrophy/chemically induced, Atrophy/diagnosis, Atrophy/epidemiology, Disease Progression, Dose-Response Relationship, Drug, Female, Fluorescein Angiography, Fundus Oculi, Humans, Incidence, Intravitreal Injections, Macula Lutea/drug effects, Macula Lutea/pathology, Male, Prognosis, Prospective Studies, Ranibizumab/administration & dosage, Ranibizumab/adverse effects, Receptors, Vascular Endothelial Growth Factor/administration & dosage, Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors, Recombinant Fusion Proteins/administration & dosage, Recombinant Fusion Proteins/adverse effects, Risk Factors, Switzerland/epidemiology, Tomography, Optical Coherence, Visual Acuity, Wet Macular Degeneration/diagnosis, Wet Macular Degeneration/drug therapy
Pubmed
Web of science
Création de la notice
01/02/2018 20:31
Dernière modification de la notice
15/01/2021 7:08
Données d'usage